Investing News

Pfizer Earnings Weighed Down Again by Dwindling COVID Sales

The company reiterated its recent reduction in full-year sales guidance by $9 billion as it doubled down on efforts to trim costs.

Articles You May Like

Shhh! 3 Secret Lithium Stocks Flying Below Wall Street’s Radar
Optimal Use of Financial Leverage in a Corporate Capital Structure
How to Establish a Blind Trust
Stock Market Crash Warning: Don’t Get Caught Holding These 3 Blue-Chip Stocks
Corporate Espionage: Fact and Fiction